Ophthalmology

Structure of the eye
#Breye Therapeutics #Financing #Ophthalmology #Retinal diseases

Breye raises €67.5 million for retinal disease therapies

Breye Therapeutics has closed an over-subscribed €67.5 million Series A financing round.   The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new investors including the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures… Read More

#Business & Investment #News

#Biotech #Exonate #Ophthalmology

Eye disease specialist Exonate appoints Hellebø as CEO 

Biotechnology company Exonate has appointed Olav Hellebø as Chief Executive Officer.  Exonate, which specialises in small-molecule therapeutics for patients with retinal vascular diseases, says Hellebø will lead the company as it strengthens its executive team and advances toward key clinical and corporate milestones, including initiating a Phase IIb clinical trial of… Read More

#News

#Drug discovery #Ophthalmology

Web series unpacks the innovation pathway in ophthalmology

Eyecelerator, Unither Pharmaceuticals and Ora have announced the launch of ‘Eye to Market’, a new web series dedicated to accelerating understanding of how ophthalmic innovations move from scientific insight to real-world adoption.   The series will bring together leaders across research, clinical development, manufacturing, and commercialisation to unpack… Read More

#News

Patient with dry eye disease using eye drops
#Aldeyra Therapeutics #Dry eye #FDA #Ophthalmology

FDA finds lack of evidence for dry eye disease drug approval

Aldeyra Therapeutics has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease.   The CRL states that there is “a lack of substantial evidence consisting of adequate… Read More

#News #Regulatory

Human eye
#Clinical trial #Ophthalmology #Preclinical development #Revvity

Preclinical advancements in ophthalmology drug development

Dr Jess Pesner and Caleb Proctor, Revvity, explore the use of in vivo, in vitro models, and in silico models in the quest for new treatments for diseases of the eye. Within drug and device approval paths, regulated steps protect the well-being of the public and offer hope for those who may be battling a disease or a life event that may currently not… Read More

#Exclusive Content

Diabetic eye disease
#Axol Bioscience #Ophthalmology #Stem cells

Axol to progress eye disease treatments with new acquisition 

Stem cell technologies company Axol Bioscience has acquired the ophthalmology business of Newcells Biotech.  The acquisition of Newcells’ ophthalmology business includes its specialist team, facilities and intellectual property related to supply of proprietary iPSC-derived products and ophthalmology research services to biopharma, biotechnology and CRO customers across Europe and… Read More

#News

Eye
#Advanced Therapies #FDA #Gene editing #Gene therapy #GenEditBio #Genetic diseases #Ophthalmology #Phase I trial

GenEditBio gets green light for in vivo genome-editing programme

The US Food and Drug Administration (FDA) has cleared GenEditBio to initiate Phase I/II CLARITY trial activities for its lead in vivo genome-editing programme GEB-101 for TGFBI corneal dystrophy.  The Phase 1/2 CLARITY trial will collect initial data on the safety, tolerability and efficacy of GEB-101 in corneal dystrophy patients… Read More

#News #Regulatory #Trending News

#Business #Eli Lilly #MeiraGTx #Ophthalmology

MeiraGTx partners with Eli Lilly in ophthalmology 

Genetic medicines company MeiraGTx has announced a strategic partnership with Eli Lilly to develop and commercialise genetic medicines in ophthalmology.  The deal, worth $475 million, will see MeiraGTx grant Lilly worldwide exclusive rights to its AAV-AIPL1 programme for treatment of Leber congenital amaurosis 4 (LCA4). LCA4 is one of the… Read More

#Business & Investment #News

#Astellas Pharma #Drug discovery #Interview #Ophthalmology

Astellas’ holistic strategy for drug discovery and development

Megan Thomas spoke to Leon Moore, Head of Global Brand Strategy & Marketing at Astellas, about how the company’s new Asset Maximization Teams are fostering collaboration and improving outcomes. MT: Astellas recently implemented a new structure, for its research, development and commercial teams to get innovative medicines to patients, faster. Read More

#Business & Investment #Exclusive Content

Screening patient for AMD
#AMD #Clinical trial #Complement Therapeutics #FDA #Gene therapy #Geographic atrophy #Ophthalmology

FDA clears gene therapy trial in geographic atrophy

The US Food and Drug Administration (FDA) has cleared Complement Therapeutics’ Investigational New Drug (IND) application for CTx001, the company’s lead gene therapy candidate.   The IND clearance enables initiation of the Opti-GAIN Phase I/II clinical trial in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).   CTx001… Read More

#News #Regulatory

Eye
#Age-related diseases (ARDs) #AMD #Fast Track designation #FDA #Ophthalmology #Sanofi

FDA fast-tracks Sanofi’s AMD gene therapy

Sanofi’s investigational one-time intravitreal gene therapy for the treatment of neovascular age-related macular degeneration (AMD) has been granted fast track designation by the US Food and Drug Administration (FDA).   Sanofi’s SAR402663 is currently being evaluated in a Phase I/II clinical trial for patients with neovascular AMD. The gene therapy… Read More

#News #Regulatory

Eye health ophthalmology
#Clinical trials #Drug discovery #Gene therapy #Ophthalmology

Advancing gene-agnostic therapies for inherited retinal diseases 

DDW’s Megan Thomas speaks with Dr Arun Upadhyay, Chief Scientific Officer, Head of Research & Development at Ocugen, about the development of gene-agnostic modifier therapies for inherited retinal diseases, highlighting pathway discovery, preclinical models, dosing strategies, biomarker integration, and the potential expansion of this approach beyond ophthalmology.  MT: How does… Read More

#Exclusive Content #News

Patient receiving eye drops
#Exonate #Ophthalmology #Phase II trial

Plans for Phase IIb trial of EXN407 for diabetic eye disease

Exonate has announced plans to initiate a Phase IIb clinical trial for its lead candidate, EXN407. The Clinical Evaluation of a New Eye Drop for Alleviating Retinopathy in Diabetic Eye Disease (CLEAR-DE) trial will further evaluate the clinical efficacy, optimal dosing and safety profile of EXN407 in patients… Read More

#News

Eye
#Boehringer Ingelheim #Collaboration #Ophthalmology #Re-Vana Therapeutics

Boehringer and Re-Vana partner on long-acting ophthalmic therapies

Boehringer Ingelheim and Re-Vana Therapeutics have announced a strategic collaboration and license agreement to develop first-in-class extended-release therapies for eye diseases.  Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients.   Re-Vana’s drug delivery technology is designed to release treatments slowly over… Read More

#Business & Investment #News

#Atsena Therapeutics #Clinical trial #FDA #Gene therapy #Ophthalmology

Atsena expedites gene therapy for X-linked retinoschisis

The US Food and Drug Administration (FDA) has agreed to the expansion of Atsena Therapeutics’ ongoing Phase I/II LIGHTHOUSE study of ATSN-201 into a continuous Phase I/II/III trial in the treatment of X-linked retinoschisis (XLRS).   “This regulatory milestone marks another significant step toward delivering a potentially first- and best-in-class gene… Read More

#News #Regulatory